NAD+ IV Therapy Contraindications: Who Should Avoid It and Why

At a Glance

NAD+ IV therapy has earned a prominent place in integrative and longevity medicine — and for good reason. The coenzyme is central to mitochondrial oxidative phosphorylation, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. Replenishing NAD+ systemically can reverse measurable metabolic decline in older adults and support recovery from a wide range of chronic conditions.

But “widely beneficial” is not the same as “universally safe.” In my clinical work I have seen patients present for NAD+ infusions who were, on careful screening, not good candidates — at least not yet, and not at standard doses. The most common reasons: an unresolved malignancy, a haemolytic anaemia triggered by oxidative stress, or a cardiac conduction issue that can flare when infusion rate is too fast.

This article gives you the full contraindication framework I use — mechanism, evidence, and practical guidance for each.

Why NAD+ Is Not Uniformly Beneficial

Before listing contraindications, it helps to understand why a molecule associated with cellular health can ever be harmful.

NAD+ feeds both repair and proliferation. The same pathways NAD+ activates — particularly PARP1/2 for DNA repair and CD38-mediated signalling — also support rapidly dividing cells. In a person free of cancer, this is beneficial. In a person with an active tumour, it could theoretically accelerate division or support resistance to treatment.

Infusion rate matters independently of the molecule. Even in healthy adults, infusing NAD+ too quickly causes transient flushing, chest tightness, nausea, and palpitations — not because the NAD+ itself is toxic but because rapid systemic delivery activates mast cells and alters catecholamine dynamics transiently. This means the method of administration creates its own risk category, separate from the molecule’s biological effects.

Individual enzyme variants change the redox math. Certain heritable enzyme deficiencies — most notably G6PD — mean that the oxidative flux generated by high-dose NAD+ is more than the cell can buffer. The result can be haemolysis.

With that context established, here are the clinical contraindications.

Contraindication 1: Active or Recently Treated Malignancy

This is the most debated contraindication in the field — and the one I take most seriously.

The evidence

NAD+ is essential for PARP-mediated DNA strand-break repair. Cancer cells are known to upregulate both PARP and CD38 (which consumes NAD+) to survive chemotherapy and radiotherapy. Several in-vitro studies show that exogenous NAD+ supplementation supports tumour cell survival under oxidative stress. A 2022 review in Cancers noted that while NAD+ depletion strategies (NAMPT inhibitors) are actively being trialled as anti-cancer agents, the converse — NAD+ repletion — has received far less safety scrutiny in oncological contexts.

This creates an uncomfortable gap: we have mechanistic reasons to be concerned, limited clinical safety data, and understandably high patient demand (many cancer patients seek metabolic support therapies during or after treatment).

My clinical approach

• During active chemotherapy or radiotherapy: I defer NAD+ IV therapy until treatment concludes. The theoretical interference with PARP-dependent repair responses — both tumour and normal tissue — introduces too many unknowns.
• Within 6 months of completing treatment: Case-by-case evaluation in consultation with the treating oncologist. Some haematological malignancies and sarcomas have higher theoretical risk than localised solid tumours fully resected with clear margins.
• >12 months in remission with no evidence of disease: NAD+ IV therapy can generally be considered, starting at lower doses (250 mg) and monitoring inflammatory markers.
• Thymosin alpha-1 and other immune-modulatory peptides often feature in cancer-survivor recovery plans; I introduce NAD+ alongside these only after haematology has cleared the patient for oxidative therapies.

Contraindication 2: G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 400 million people worldwide and is far more prevalent than most practitioners realise, particularly in patients of Mediterranean, African, Middle Eastern, and South-East Asian heritage.

The mechanism

G6PD is the rate-limiting enzyme of the pentose phosphate pathway, which generates NADPH — the reducing agent the red blood cell depends on to maintain glutathione in its reduced (protective) form. Without adequate NADPH, red blood cells cannot neutralise oxidative stress, and haemolysis results.

NAD+ infusions generate systemic oxidative flux during metabolism. In a G6PD-sufficient individual, this is well-buffered. In a G6PD-deficient patient, the same oxidative burst can overwhelm red-cell antioxidant defences, triggering acute haemolytic anaemia.

Clinical implications

Screen all patients with a family history of haemolysis, unexplained dark urine after infections or medications, or relevant ancestry. A simple quantitative G6PD enzyme assay (not a spot test in suspected carriers) is adequate. Mild deficiency (>30% enzyme activity) in an asymptomatic patient may permit very slow, low-dose NAD+ infusions with appropriate monitoring — but I would not start without explicit informed consent and a haemoglobin baseline.

Severe deficiency (<10% activity) is an absolute contraindication to high-dose NAD+ IV.

Contraindication 3: Uncontrolled Cardiac Arrhythmias

NAD+ infusions delivered faster than 1–2 mg per minute routinely cause transient palpitations and chest tightness in otherwise healthy adults. In most patients, slowing the infusion rate resolves the symptoms within minutes. In patients with pre-existing arrhythmias, this transient perturbation can trigger sustained events.

Underlying physiology

Rapid NAD+ infusion is thought to transiently increase catecholamine sensitivity and stimulate cardiac mast cells, producing a sympathomimetic-like effect. Patients with reentrant tachyarrhythmias (AVNRT, atrial flutter), prolonged QT syndrome, or poorly rate-controlled atrial fibrillation are at elevated risk during the infusion window.

Practical guidance

• Obtain an ECG before the first infusion in any patient over 55 or with a cardiac history.
• Patients with well-controlled AF (rate <90 bpm at rest, on stable therapy) are generally suitable at 0.5 mg/min starting rate with cardiac monitoring during the first session.
• Uncontrolled AF, flutter, or any history of ventricular arrhythmia: cardiology clearance before proceeding.
• Patients with long QT syndrome or on QT-prolonging medications (certain antidepressants, quinolone antibiotics, antipsychotics): defer or substitute with oral NMN/NR protocols, which carry no infusion-rate risk.

Contraindication 4: Acute Infectious Illness

NAD+ metabolism is deeply intertwined with immune activation. During acute infection, NF-κB–driven inflammation consumes NAD+ at an accelerated rate (CD38 upregulation is a characteristic feature of macrophage activation), which already depletes systemic stores. An IV infusion during this window adds a large exogenous NAD+ load to an already-dysregulated metabolic environment.

The clinical concern is not that NAD+ causes infection to worsen — there is no direct evidence of this — but rather that the pro-inflammatory context amplifies infusion-related side effects (flushing, nausea, headache) and that patients are generally in a poor state to tolerate the mild haemodynamic shifts that come with rapid infusion.

My rule: no NAD+ IV during any febrile illness or within 72 hours of a fever resolving. For patients with chronic infections being managed with antibiotics (Lyme disease, chronic EBV reactivation), timing the infusion away from the Herxheimer reaction window makes sense — typically 3–4 days after antibiotic dosing.

Contraindication 5: Pregnancy and Breastfeeding

No safety data exist for high-dose intravenous NAD+ in pregnant or breastfeeding women. Animal studies using NAD+ precursors show mixed results: some demonstrate benefit in specific models of placental dysfunction, but others show interference with normal developmental NAD+ signalling.

Given the complete absence of human safety data in this population, and given that the potential consequences of placental or foetal harm are severe and irreversible, high-dose IV NAD+ is contraindicated in pregnancy and breastfeeding. Low-dose dietary NMN through food sources is not equivalent and is not subject to the same concern.

Contraindication 6: Severe Hepatic or Renal Impairment

NAD+ precursor metabolism occurs primarily in the liver (via the Preiss-Handler and salvage pathways), and renal clearance handles a portion of metabolic byproducts including nicotinamide (NAM) and its methylated derivatives. In patients with advanced liver disease (Child-Pugh C) or eGFR below 30 mL/min/1.73 m², these clearance mechanisms are significantly impaired.

Accumulation of NAM and 1-methylnicotinamide at high concentrations has been associated with adverse effects in animal models. While clinical cases in humans are rare, the pharmacokinetic uncertainty in severely impaired patients argues for caution.

Practical guidance: patients with Child-Pugh A–B hepatic impairment or eGFR 30–60 can receive NAD+ IV at reduced dose (250 mg maximum) with more frequent laboratory monitoring. Child-Pugh C or eGFR <30: use oral NMN/NR protocols only until organ function improves.

Relative Contraindications Worth Noting

Several conditions are not absolute contraindications but warrant additional monitoring or dose modification:

How I Screen Patients Before NAD+ IV

My standard pre-infusion workup includes:

1. Full blood count — screen for anaemia, any suggestion of haemolysis
2. Metabolic panel — renal function (creatinine, eGFR), liver enzymes (ALT, AST, ALP, GGT)
3. 12-lead ECG — mandatory for patients over 50 or with any cardiac history
4. G6PD quantitative assay — for all patients with relevant ancestry or history
5. Cancer history review — date of last active treatment, current surveillance status, oncologist consultation if <12 months in remission
6. Medication reconciliation — specifically reviewing QT-prolonging agents, immunosuppressants, anticoagulants
7. Pregnancy test — for all women of reproductive age

This takes approximately 10–15 minutes as part of a consultation and prevents the majority of adverse events I’ve seen in patients who received NAD+ IV at facilities without formal screening protocols.

Related Articles

• NAD+ IV Therapy: What to Expect During Your Infusion — session-by-session breakdown for first-timers
• NAD+ IV Side Effects: Causes and How to Minimise Them — why flushing, nausea and chest tightness happen and how to prevent them
• NAD+ vs NMN vs NR: Which Raises Cellular NAD+ Most Effectively? — choosing the right NAD+ precursor strategy
• Rapamycin Dosage and Protocol for Longevity — another longevity therapy with its own contraindication profile
• Ozone Therapy Risks and Contraindications — parallel safety guide for IV ozone

References

1. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–547. PubMed
2. Navas LE, Carnero A. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6(1):2. PubMed
3. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141. PubMed
4. Chini CCS, Zeidler JD, Kashyap S, Warner G, Chini EN. Evolving concepts in NAD+ metabolism. Cell Metab. 2021;33(6):1076–1087. PubMed
5. Berger F, Ramírez-Hernández MH, Ziegler M. The new life of a centenarian: signalling functions of NAD(P). Trends Biochem Sci. 2004;29(3):111–118. PubMed
6. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PubMed
7. Nikiforov A, Dölle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem. 2011;286(24):21767–21778. PubMed